Colgate's Periogard mouthwash recalled in 11 countries
Global consumer healthcare brand, Colgate-Palmolive, has been forced to recall bottles of its Periogard mouthwash after contamination fears.
Tests carried out by the Medicines and Healthcare Products Regulatory Agency (MHRA) found the bacteria Burkholderia was present in a selection of Periogard mouthwash samples.
As a result, the mouthwash has been removed from sale in countries across Europe and Australasia, 11 in total.
It has been estimated 50,000 bottles of Colgate-Palmolive’s Periogard product, which is sold under different brand names in other countries, have been recalled in the UK alone.
To read the latest edition of Healthcare Global, click here
- Hand transplant operation soon to take place in the UK
- Multi-cancer drug treatment trials begin in patients
- Movember to raise global awareness of prostate cancer
Although it is thought the Burkholderia bacteria should have no adverse effects in healthy people, there is an infection risk in users who are suffering from lung conditions, such as lung disease or cystic fibrosis, or a weakened immune system.
A statement issued by the UK arm of Colgate-Palmolive read: “The presence of micro-organisms has been detected in some retained production samples of Periogard.
“Under certain circumstances, these micro-organisms may be harmful to individuals with compromised health.
“Accordingly, in order to ensure the safety of our consumers, in co-operation with the Medicine and Health Regulatory Authority, Colgate-Palmolive UK is recalling all Periogard.
“No other Colgate mouthwash products are included in the recall,” it said.
Periogard is a medicinal type of mouthwash, typically used in patients who have recently undergone mouth or gum surgery.
It is available in retail outlets, pharmacies, hospitals and dental surgeries.
The MHRA’s Director of Inspection, Enforcement and Standards, Gerald Heddell, commented on the recall. He said: “For healthy people there should be no problems.
“However, for some there could be a small potential risk of infection. If people do have any suspected side-effects then they should contact their GP.”
Colgate-Palmolive is also advising people to call its helpline with any queries or commented regarding the recall.
People are being told to call 00 800 321 321 32 between the hours of 08:30-17:30 on Monday’s, Tuesday’s, Wednesday’s and Friday’s and between 08:30-15:00 on Thursday’s.
The helpline will also be offering advice on refunds and returns of the mouthwash.
Our magazine is now available on the iPad. Click here to download it.
Dubai's new smart neuro spinal hospital: need to know
We take a look at Dubai's new smart hospital.
What: The Neuro Spinal Hospital and Radiosurgery Centre is a new hospital featuring state-of-the-art technology for spinal, neurosurgical, neurological, orthopaedic, radiosurgery and cancer treatments. The 700 million AED hospital, (equivalent to £138 million), has 114 beds, smart patient rooms, and green spaces for patient rehabilitation, and is four times the capacity of its former premises in Jumeirah. It is also the UAE’s first hospital to have surgical robots.
Where: The hospital is located in the Dubai Science Park. Founded in 2005, Dubai Science Park is home to more than 350 companies from multinational corporations in life sciences, biotechnology and research; over 4,000 people work here each day.
Who: The UAE's Neuro Spinal Hospital and Radiosurgery Centre was first established in Jumeirah in 2002 by Dr. Abdul Karim Msaddi, as the first as the first "super-specialty" neuroscience hospital.
Why: With advanced diagnosis and robotics, the hospital will provide care across neuroscience, spine, orthopaedics and oncology for people residing in the UAE, as well as international patients.
Prof. Abdul Karim Msaddi, Chairman and Medical Director of the hospital, said: “We are proud to bring world-class healthcare services to Dubai and believe our next-generation hospital will be a game-changer for the emirate’s and the region’s medical industry.
"It will not only significantly increase the availability of specialist neuroscience and radiosurgery treatments and provide better patient care but help attract and develop local and international talent. Investing in the new centre represents our continued faith in the resilience of the region’s economy, as well as a testament to our ongoing drive towards healthcare innovation in the UAE.”